EN 1530 Base en es it fr

EN 1530 Base Brand names, EN 1530 Base Analogs

EN 1530 Base Brand Names Mixture

  • No information avaliable

EN 1530 Base Chemical_Formula


EN 1530 Base RX_link


EN 1530 Base fda sheet

EN 1530 Base msds (material safety sheet)

EN_1530_Base MSDS

EN 1530 Base Synthesis Reference

No information avaliable

EN 1530 Base Molecular Weight

327.374 g/mol

EN 1530 Base Melting Point

200 - 205 oC

EN 1530 Base H2O Solubility


EN 1530 Base State


EN 1530 Base LogP


EN 1530 Base Dosage Forms


EN 1530 Base Indication

For the complete or partial reversal of narcotic depression, including respiratory depression, induced by opioids including natural and synthetic narcotics, propoxyphene, methadone and the narcotic-antagonist analgesics: nalbuphine, pentazocine and butorphanol.

EN 1530 Base Pharmacology

Naloxone is an opiate antagonist and prevents or reverses the effects of opioids including respiratory depression, sedation and hypotension. Also, it can reverse the psychotomimetic and dysphoric effects of agonist-antagonists such as pentazocine. Naloxone is an essentially pure narcotic antagonist, i.e., it does not possess the "agonistic" or morphine-like properties characteristic of other narcotic antagonists; naloxone does not produce respiratory depression, psychotomimetic effects or pupillary constriction. In the absence of narcotics or agonistic effects of other narcotic antagonists, it exhibits essentially no pharmacologic activity.

EN 1530 Base Absorption

Well absorbed following intramuscular injection.

EN 1530 Base side effects and Toxicity

No information avaliable

EN 1530 Base Patient Information

No information avaliable

EN 1530 Base Organisms Affected

Humans and other mammals